Novo Nordisk recalled six batches of the GlucaGen HypoKit, which is indicated to treat severe hypoglycemia in patients with diabetes who are receiving insulin.
The company received two customer complaints from the United Kingdom and Portugal involving detached needles on the syringe with sterile water for injection, according to an FDA news release.
Novo Nordisk said it was not aware of any adverse events resulting from the use of the recalled batches. The company added that an estimated four of the 71,215 recalled pens could be defective. The affected products were distributed starting Feb. 15.